Provided by Tiger Trade Technology Pte. Ltd.

Incyte

123.22
-1.1500-0.92%
Post-market: 123.410.1931+0.16%19:30 EDT
Volume:1.48M
Turnover:182.70M
Market Cap:24.98B
PE:15.70
High:124.00
Open:122.66
Low:121.61
Close:124.37
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.59
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.94
PE(LYR):19.22

Loading ...

Halozyme Partners with Incyte on Enhanze Subcutaneous Formulation for Inca033989 Antibody

Reuters
·
Jul 20

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of Inca033989 Using Its Enhanze® Technology

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - Eligible to Receive Royalties on Net Sales of Enhanze Medicines

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - to Receive Upfront Payment and Eligible for Milestone Payments from Incyte

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - Incyte Granted Rights to Develop Enhanze with Mutcalr Program and Option for Two Additional Targets

THOMSON REUTERS
·
Jul 20

Incyte (INCY) Reports Promising Latarcibart Data As Global Phase 3 Begins

Simply Wall St.
·
Jul 17

Incyte Corp. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 17

Incyte CMO Steven H. Stein Disposes of 53,155 Shares Worth $6.05 Million

Reuters
·
Jul 17

BofA Securities Raises Incyte Price Target to $136 From $124

MT Newswires Live
·
Jul 15

Incyte price target raised to $136 from $124 at BofA

TIPRANKS
·
Jul 15

Incyte : Bofa Global Research Raises Price Objective to $136 from $124

THOMSON REUTERS
·
Jul 15

Incyte: Early Strength in VGA039 Offsets Execution Risks; Salveen Richter Reiterates Hold and $100 Price Target

TIPRANKS
·
Jul 14

Incyte is Maintained at Overweight by Barclays

Dow Jones
·
Jul 14

Incyte: VGA039 Data Reinforces Diversification Strategy as Analyst Reiterates Hold and Keeps $103 Price Target Unchanged

TIPRANKS
·
Jul 14

Incyte price target raised to $134 from $117 at Barclays

TIPRANKS
·
Jul 14

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 14

Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says

MT Newswires Live
·
Jul 13

Jefferies Adjusts Price Target on Incyte to $105 From $100, Maintains Hold Rating

MT Newswires Live
·
Jul 13

Incyte announces safety, efficacy data from VGA039 study

TIPRANKS
·
Jul 13

Incyte's Latarcibart Cuts Bleeding Rates in Phase 1/2 Trial in Patients With von Willebrand Disease

MT Newswires Live
·
Jul 13